Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Articles

Correspondence

Correspondence to letter to the editor on “Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement”


Published online: October 30, 2026

1Medical Data Analytics Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China

2State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China

3Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China

4Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea

Corresponding authors : Vincent Wai-Sun Wong Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, 9/F, Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, Hong Kong Tel: +852-3505-1299, Fax: +852-2637-3852, Email: wongv@cuhk.edu.hk
Seung Up Kim Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea Tel: +82-2-2228-1944, Fax: +82-2-393-6884, E-mail: KSUKOREA@yuhs.ac

Editor: Han Ah Lee, Chung-Ang University College of Medicine, Korea

• Received: February 23, 2026   • Accepted: March 6, 2026

Copyright © 2026 by The Korean Association for the Study of the Liver

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 226 Views
  • 9 Download
Dear Editor,
We thank Zhang et al. [1] and Zhao and Liu [2] for their thoughtful letter regarding our multicenter analysis of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who have concordant versus discrepant fibrosis-4 index (FIB-4) and liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) results. Their comments help sharpen how these data can be used in day-to-day practice.
Our study was originally designed to address a common issue encountered in daily clinical practice, i.e., what to do when non-invasive tests (NITs) of liver fibrosis disagree, with liver-related events (LREs) as the target outcomes. This focus reflects both the intended use of these tests for fibrosis staging and stratification of liver complication risk, and current clinical care pathways recommending a two-step approach with FIB-4 followed by LSM if FIB-4 is elevated. We found that discrepant results are frequent in tertiary settings, and when discrepant, LSM more often tracked with histologic severity. We share the emphasis of Zhang and colleagues on absolute LRE risk. In our article, we reported the 5-year cumulative incidence of LREs, hepatic decompensation, and hepatocellular carcinoma in individuals with concordant and discordant NITs based on different commonly used cut-offs. Absolute LRE risk in discordant groups remained low over 5 years, while concordantly high FIB-4 and LSM conferred the highest LRE risk [3].
We agree, however, that the prognosis of MASLD is frequently shaped by cardiovascular disease (CVD) and cancer [4], and that a low LRE risk should not be interpreted as a low overall risk of adverse clinical outcomes. Previous studies show that MASLD is independently associated with incident CVD [5], and that serum fibrosis scores such as FIB-4 are also associated with major adverse cardiovascular events [6]. At the same time, evidence is heterogeneous across populations, endpoints, and age adjustments [7]. Taken together, we view NITs of liver fibrosis primarily as liver tools with the strongest and most consistent prognostic value for LREs; their incremental role for predicting long-term CVD compared to more specific tools such as the PREVENT equation remains unclear [8]. Consistent with this view, guideline frameworks that included two-step clinical care pathway do so to triage hepatology care, but not to replace standard CVD risk assessment or management.
Therefore, discordant NIT results should not undermine the importance of cardiometabolic prevention, especially in individuals with high FIB-4 and low LSM, which may reflect broader cardiometabolic vulnerability (older age, low platelets, and comorbidities) rather than advanced fibrosis. CVD risk remains a parallel care priority in MASLD. Consistent with current MASLD guidelines, patients with FIB-4 between 1.3 and 2.67 should receive lifestyle interventions and intensified management of cardiometabolic risk factors, and can repeat FIB-4 at 1 year [9]. We also agree that changes in cardiometabolic therapies over time and differences in follow-up intensity can impact observed outcomes. Following the guideline recommendations, we support periodic reassessment every 1–3 years according to the patient’s risk profile, so NITs reflect the latest risk and enable timely referral when risk is elevated.
We agree that our tertiary-center cohort may over-represent individuals with a more advanced liver disease and that the prevalence of discordant NITs could differ in community settings. In our study, VCTE was performed following standard protocol and training by the manufacturer, with ≥10 valid acquisitions for every patient. Yet, operator experience and device availability indeed vary across care settings. These practical issues argue for external validation in primary care cohorts and quality criteria for VCTE examination. Notably, an analysis of National Health and Nutrition Examination Surveys 2017–2020 also reported around 30% of discordance between FIB-4 and LSM in the general population, confirming that this issue extends beyond tertiary cohorts, albeit in a different population composition [10].
A key question for the healthcare system is how best to select patients for second-line testing and follow-up testing or plan when NITs are discordant. Our previous analysis using the same multinational cohort showed that a two-step approach of FIB-4 followed by LSM in those with elevated FIB-4 achieved prognostic performance comparable to performing LSM in all patients, supporting the stepwise, resource‑efficient use of NITs [11]. Consistent findings from primary‑care settings suggest that similar two‑step pathways can effectively triage referrals outside hepatology clinics [12]. To inform follow‑up decisions by hepatologists, we estimated 5‑year LRE risk using an LSM threshold of 12 kPa among patients with FIB‑4 <1.3, i.e., 0.13% (95% confidence interval 0.01–0.70) for LSM 8–12 kPa, and 1.81% (0.75–3.75) for LSM ≥12 kPa. At the same time, false-positive referrals triggered by FIB‑4 ≥1.3 remain a concern and have been reported when subsequent LSM <8 kPa [10]. Similarly, in our study, two‑thirds of discordant cases had elevated FIB‑4 but low LSM, and they carried a low absolute risk of LRE. While novel NITs have been developed for primary care, e.g., LiverRisk score [13], MAF-5 [14], and LiverPRO [15], may complement and eventually substitute FIB-4 in low-prevalence settings, they require more head‑to‑head external evaluations of prognostic performance before routine adoption.
We are grateful for the letters’ constructive suggestions and reiterate that fibrosis NITs are liver assessments that correlate most strongly with liver outcomes. Although their performance in predicting CVD can vary across settings, this variability should not diminish their value for the purpose they were designed to serve. We agree that reassessment every 1–3 years, depending on individual risk profile, keeps the NITs up to date and enables timely referral when risk increases. We share the authors’ interest in complementary analyses, including cause-specific mortality, treatment trajectories, and follow-up patterns. We also agree that carefully designed longitudinal studies are needed to refine referral cut-offs across clinical settings and to guide reassessment and management of discordant phenotypes spanning liver and cardiometabolic risk.

Authors’ contribution

The authors contributed equally to the literature review and drafting of the reply letter. They all approved the final version of the manuscript.

Acknowledgements

The study was supported in part by the Noncommunicable Chronic Diseases-National Science and Technology Major Project of China (2023ZD0508700), General Research Fund by the Hong Kong SAR Government (14106923), and Direct Grant of The Chinese University of Hong Kong (2024.065).

Conflicts of Interest

Terry Yip has served as an advisory committee member for Altimmune, Gilead Sciences, and GSK, and as a speaker for Gilead Sciences. He has received a research grant from Gilead Sciences. Vincent Wong served as a consultant or advisor for AbbVie, AstraZeneca, Boehringer Ingelheim, Echosens, Eli Lilly, Gilead Sciences, Merck, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, and TARGET PharmaSolutions; a speaker for Abbott, AbbVie, AstraZeneca, Echosens, Gilead Sciences, and Novo Nordisk; an independent non-executive director for Furui; and a cofounder of Illuminatio Medical Technology. He has received a research grant from Gilead Sciences. Seung Up Kim has served on the advisory committee for Gilead Sciences, GSK, Bayer, Novo Nordisk, and Eisai; served as a speaker for Gilead Sciences, GSK, Bayer, Eisai, AbbVie, EchoSens, MSD, Bristol-Myers Squibb, Hanhwa, Yuhan, Samil, PharmaKing, Celltrion, and Bukwang; and received research grants from AbbVie and Bristol-Myers Squibb.

The funder of the study did not have a role in study design, data collection, data analysis, data interpretation, or manuscript preparation. Echosens provided logistic support for investigator coordination and meeting organization, but did not provide funding for this study.

CVD

cardiovascular disease

FIB-4

Fibrosis-4 index

LREs

liver-related events

LSM

liver stiffness measurement

MALO

major adverse liver outcomes

MASLD

metabolic dysfunction-associated steatotic liver disease

NITs

non-invasive tests

VCTE

vibration-controlled transient elastography
  • 1. Zhang Z, Yu Z, Wu G. Discordant FIB-4 and liver stiffness in metabolic dysfunction-associated steatotic liver disease: toward clinically coherent risk stratification: letter to the editor on “histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement”. Clin Mol Hepatol 2026;32:e297-e299.
  • 2. Zhao J, Liu L. Navigating discordant non-invasive fibrosis assessments in metabolic dysfunction-associated steatotic liver disease: implications for generalizability, clinical decision-making, and resource allocation: letter to the editor on “histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement”. Clin Mol Hepatol 2026;32:e300-e302.
  • 3. Rabbat J, Yang B, Lee HW, Lin H, Tsochatzis E, Petta S, et al. Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement. Clin Mol Hepatol 2026;32:289-304.
  • 4. Lin H, Yip TC, Zhang X, Li G, Tse YK, Hui VW, et al. Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease. Hepatology 2023;77:573-584.
  • 5. Moon JH, Jeong S, Jang H, Koo BK, Kim W. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study. EClinicalMedicine 2023;65:102292.
  • 6. Zhou XD, Li YT, Kim SU, Yip TC, Petta S, Nakajima A, et al. Longitudinal changes in fibrosis markers: monitoring stiffness/fibrosis progression and prognostic outcomes in MASLD. Clin Gastroenterol Hepatol 2026;24:394-406.
  • 7. Guan L, Li L, Zou Y, Zhong J, Qiu L. Association between FIB-4, all-cause mortality, cardiovascular mortality, and cardiovascular disease risk among diabetic individuals: NHANES 1999-2008. Front Cardiovasc Med 2023;10:1172178.
  • 8. American Heart Association. The American Heart Association PREVENT™ Online Calculator. AHA web site, <https://professional.heart.org/en/guidelines-and-statements/preventcalculator>. Accessed 22 Feb 2026.
  • 9. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol 2024;81:492-542.
  • 10. Chang M, Chang D, Kodali S, Harrison SA, Ghobrial M, Alkhouri N, et al. Degree of discordance between FIB-4 and transient elastography: an application of current guidelines on general population cohort. Clin Gastroenterol Hepatol 2024;22:1453-1461.e2.
  • 11. Yip TC, Lee HW, Lin H, Tsochatzis E, Petta S, Bugianesi E, et al. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease. J Hepatol 2025;83:304-314.
  • 12. Kjaergaard M, Lindvig KP, Thorhauge KH, Andersen P, Hansen JK, Kastrup N, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol 2023;79:277-286.
  • 13. Serra-Burriel M, Juanola A, Serra-Burriel F, Thiele M, Graupera I, Pose E, et al. Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study. Lancet 2023;402:988-996.
  • 14. van Kleef LA, Francque SM, Prieto-Ortiz JE, Sonneveld MJ, Sanchez-Luque CB, Prieto-Ortiz RG, et al. Metabolic dysfunction-associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction. Gastroenterology 2024;167:357-367.e9.
  • 15. Lindvig KP, Thorhauge KH, Hansen JK, Kjærgaard M, Hansen CD, Johansen S, et al. Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort study. Lancet Gastroenterol Hepatol 2025;10:55-67.

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

Include:

Correspondence to letter to the editor on “Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement”
Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:
Include:
Correspondence to letter to the editor on “Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement”
Close
Correspondence to letter to the editor on “Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement”
Correspondence to letter to the editor on “Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement”